Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.
The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation.
However, there is no standard recognition of the usage of this new technology. As such, ESOT will drive and coordinate a whitepaper about molecular biomarkers for the non-invasive diagnosis of rejection that is aimed at providing a full European landscape and address unmet clinical needs.
Topic Chairs: John Friedewald (Kidney) Marina Berenguer (Liver) & Luciano Potena (Heart)
Steering Committee for Kidney: Dany Anglicheau, Oriol Bestard, John Friedewald, Claire Tinel, Sook Park, Joana Sellares
Steering Committee for Heart: Maria Crespo Leiro, Kiran Khush, Ingvild Birschmann, Javier Segovia, Andriana Nikolova, Annamaria Minervini
Steering Committee for Liver: Amelia Heissheimer, Eleonora de Martin, Valeria Mas, Josh Levitsky, Haseeb Zubair, Alina Lutu, Nabeel Wahid
Steering Committee for Lung: Sean Agbor-Enoh, Robin Vos
Heart and Lung
Kidney
Liver